Regeneron begins Covid-19 antibody cocktail late-stage trial
It will test the therapy's ability to prevent infection in those who have had close exposure to a Covid-19 patient
The ultrastructural morphology exhibited by the 2019 Novel Coronavirus, which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, US January 29, 2020/Reuters
Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating Covid-19.
The trial, run jointly with the National Institute of Allergy and Infectious Diseases, would test the therapy's ability to prevent infection in those who have had close exposure to a Covid-19 patient.
Keep updated, follow The Business Standard's Google news channel
